The IL-6 increase was significantly lower in the treated groups compared to the BD group: Coversin group FC 43 (6–79) (p = 0.0005), anti-CD14 group FC 15 (4.9–24) (p < 0.0001) and the dual treatment group FC 45 (-10-100) (p = 0.0007) (Fig. 4B). Here, CD14 is linked to Behcet disease.